DPH: cash-generative regional pharma with limited liquidity and concentrated ownership
Intrinsic value VND 59,174 vs market VND 52,900, implied upside 11.9% (model confidence: low).
Tổng quan doanh nghiệp
Công ty Cổ phần Dược phẩm Hải Phòng (DPH) is an UPCoM-listed pharmaceutical company operating primarily in finished drugs and related distribution within Vietnam. Revenue has been stable but slightly contracting: VND 187.5 bn in 2023, VND 182.4 bn in 2024 and VND 181.3 bn in 2025, suggesting a mature regional franchise with modest top-line pressure. The company reports healthy margins (gross margin 29.7%, net margin 14.3%) and generates positive ROE of 10.7% and ROA of 9.0%, indicating profitable operations on a relatively asset-light base.
Luận điểm đầu tư
DPH is a cash-generative, profitable small-cap pharma with valuation metrics that appear undemanding: P/E 6.1x, P/B 0.63x and EV/EBITDA 5.3x on the latest reported ratios. Our intrinsic estimate (blend of DCF 70% / PE 30%) yields VND 59,174 per share, implying 11.9% upside to the market price of VND 52,900. The balance sheet is net cash (net debt: negative VND 14,858,315,771 reported in model inputs), supporting shareholder returns (dividend yield ~3.8%) and resilience through modest revenue declines.
Offsetting these positives, the model confidence is low and trading liquidity is limited (avg volume two weeks: 1,596 shares; UPCoM listing with 'illiquid' sanity flag). Ownership is highly concentrated: one individual holds 57.7% and the company has zero foreign room, constraining free-float and limiting the share's appeal to institutional flows. Given the low model confidence, narrow implied upside (11.9%) and execution/ liquidity risks, the upside does not sufficiently compensate for these idiosyncratic factors.
Bình luận định giá
Blend of a 10-year DCF (70%) and a PE multiple approach (30%), calibrated by isotonic mapping to a raw intrinsic value.
- Base free cash flow: VND 17,343,365,751 (input base_fcf).
- WACC: 10.05% with ke 11.1%, kd after tax 5.18%, equity weight 82.27%, debt weight 17.73%.
- Terminal growth: 4.0% and terminal value accounts for 56.81% of value (tv_pct 0.5681).
- PE component: fair PE 5.79 with cap 25; blend weights DCF 0.7 / PE 0.3 produce raw_intrinsic_value VND 88,052.3 before calibration.
- Net cash position factored: model net_debt negative VND 14,858,315,771.
The blended intrinsic value VND 59,174 implies 11.9% upside but model confidence is low (recalibrated). Key sensitivities are WACC and terminal growth; given the illiquidity flag and limited public float, execution and marketability risk reduce our conviction in the intrinsic estimate. Treat the valuation as indicative rather than high-conviction.
Quan điểm tích cực và tiêu cực
- Undemanding multiples: P/E 6.1x and P/B 0.63x versus many listed peers, supporting upside potential to intrinsic VND 59,174.
- Stable profitability: Gross margin 29.7% and net margin 14.3% with ROE 10.7% and ROA 9.0%, indicating resilient earnings power.
- Net cash on balance sheet (model net_debt negative VND 14.9 bn) supports dividends (yield ~3.8%) and lowers financial risk.
- DCF shows meaningful terminal value contribution (tv_pct 56.81%), reflecting long-lived cash generation under a conservative 4.0% terminal growth.
- Low model confidence and 'illiquid' sanity flag; average two-week volume only 1,596 shares, increasing transaction cost and exit risk.
- Highly concentrated ownership: single individual holds 57.724%, and foreign_room is 0.0%, limiting market-making and institutional demand.
- Top-line weakness: revenue fell from VND 187.5 bn in 2023 to VND 181.3 bn in 2025 (three-year CAGR negative -2.86% in growth components), suggesting limited growth runway.
- Intrinsic upside is modest at 11.9% and the confidence downgrades mean calibration could move value materially; upside may not compensate for governance and liquidity risks.
Bối cảnh ngành
DPH sits in Vietnam's listed pharmaceutical universe where valuations vary widely by scale, product mix and distribution reach; sector median implied upside is approximately 12.1% across 351 peers. Regulatory and reimbursement dynamics, along with VAS accounting differences for inventories and receivables, affect comparability across peers. State-directed credit conditions (SBV quotas) and the limited foreign ownership quotas on smaller UPCoM names can constrain capital flows; DPH has zero foreign room which reduces demand from foreign funds. For pharma peers, differences in product pipelines, distribution networks and ownership structure (SOE vs private) are common drivers of divergence in multiples.
Yếu tố rủi ro
- High ownership concentration (57.724% held by an individual) — minority liquidity and governance risks if major holder changes stance.
- Very limited trading liquidity (avg volume 2w: 1,596) and UPCoM listing marked 'illiquid' — execution risk for larger orders and wider spreads.
- Zero foreign_room — excludes foreign institutional demand and can compress valuation multiple vs peers with open foreign ownership.
- Revenue trend weak: revenue declined from VND 187.5 bn (2023) to VND 181.3 bn (2025); historical CAGR used in growth components is -2.86%.
- Model confidence is low (recalibrated) and raw intrinsic value required isotonic calibration, indicating sensitivity to input assumptions.
- Small-cap sector dynamics: peer median upside similar (12.1%) but wide dispersion exists; sector shocks or tightening on drug pricing could hit margins.
- Dividend sustainability risk if cash generation or working capital needs deteriorate despite current 3.8% yield.
Yếu tố xúc tác
- Improved free float or reduction in majority-holder stake could unlock liquidity and valuation re-rating.
- Better-than-expected revenue stabilization or reacceleration reversing the recent downtrend would support revaluation above blended intrinsic value.
- Unexpected corporate actions (M&A, strategic partnership, or change in distribution footprint) that materially expand market access.
- Quarterly results that materially exceed consensus margins or cash-generation metrics, improving model confidence.
Đánh giá pháp y tài chính
No Beneish M-Score is available (mscore null) and there are no explicit forensic red flags reported. Earnings quality is relatively high at 83.2/100, which supports reliability of reported profits. The primary forensic concerns are therefore structural: concentrated ownership (57.7%) and limited liquidity, rather than accounting manipulation signals.
Lịch sử dự báo
The model has a 10-year track record with a hit rate of 66.7% (8 in 12? — input gives 0.6667), showing a better-than-random historical performance but not flawless. Average historical upside on model calls is large (avg_upside_pct 144.6%), which likely reflects a few outsized winners; treat point estimates conservatively given the current low model confidence and the stock's illiquidity.
Được viết bởi mô hình ngôn ngữ ngày 2026-08-10 dựa trên kết quả mô hình và báo cáo tài chính của chính trang này, và có thể trích dẫn số liệu tại thời điểm đó. Đây là phân tích mô tả, không phải khuyến nghị đầu tư — không đưa ra hay hàm ý bất kỳ khuyến nghị mua, bán hay nắm giữ nào.